Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
The lack of an efficient anti-tumor T cell response contributes to the failure of anti-PD1 therapy. Here, the authors show a potential strategy to improve the therapeutic effects of anti-PD-1 antibody by simultaneously targeting IL-21 to tumor-reactive T cells in vivo.
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/e0144328845a498a9c1f543f87d37f7c |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|